Mineralocorticoid receptor antagonist use in eligible patients following acute myocardial infarction: Real world data from the Acute Coronary Syndrome Israeli Surveys: 2004–2010

Abstract Background Following the EPHESUS trial in 2003, mineralocorticoid receptor antagonist (MRA) therapy received a class I indication for the management of eligible high-risk post-MI patients. Our goal was to examine temporal trends in MRA use in eligible post-myocardial infarction (MI) patient...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of cardiology 2013-10, Vol.168 (4), p.3971-3976
Hauptverfasser:	Koifman, Edward, Kopel, Eran, Maor, Elad, Fefer, Paul, Matezky, Shlomi, Tofler, Goeffrey, Hamdan, Ashraf, Grossman, Ehud, Goldenberg, Ilan, Klempfner, Robert
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute Coronary Syndrome - drug therapy Acute Coronary Syndrome - epidemiology Acute myocardial infarction Aged Aged, 80 and over Biological and medical sciences Cardiology. Vascular system Cardiovascular Coronary heart disease Databases, Factual - trends Female Follow-Up Studies Health Surveys - trends Heart Heart failure Heart failure, cardiogenic pulmonary edema, cardiac enlargement Humans Israel - epidemiology Male Medical sciences Middle Aged Mineralocorticoid receptor antagonist Mineralocorticoid Receptor Antagonists - therapeutic use Myocarditis. Cardiomyopathies Patient Discharge - trends Prospective Studies Registries Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!